TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9124549
Drug: Arginine vasopressin
Normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine vasopressin (AVP) infusion
Study: 9038524
Drug: No preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preparation
Study: 15096395
Drug: Topiramate 100
Normalized name: topiramate 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate 100 mg/d
Study: 15727691
Drug: Low dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dosage (60 mg/d) of diisopropylamine dichloroacetate
Study: 2970853
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 60 mg/day
Study: 24904785
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg metoprolol the night before surgery
Study: 16849623
Drug: pegaptanib 0.3
Normalized name: PEGAPTANIB 0.3MG/0.09ML INTRAOCULAR SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: pegaptanib 0.3 mg intravitreous injection every 6 weeks for 48 weeks
Study: 22136978
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg monotherapy
Study: 9649101
Drug: Traditional postoperative
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional postoperative oral feeding
Study: 6383734
Drug: SCH 370
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 370 cream
Study: 6383740
Drug: Methylprednisolone 64
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 64 mg every other day (qod)
Study: 9033712
Drug: Ketoconazole cream
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole cream (2%) applied once daily
Study: 21665462
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (FOLFIRI)
Study: 29682796
Drug: JNJ‐39758979 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐39758979 300 mg once daily for 12 weeks
Study: 17615904
Drug: Zinc gluconate
Normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc gluconate (10 mg elemental zinc) added to multi-vitamin syrup containing vitamin A
Study: 2496428
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg intravenous (IV) cocaine with 2.5 mg oral bromocriptine pretreatment
Study: 2496428
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg intravenous (IV) cocaine without bromocriptine pretreatment
Study: 28606235
Drug: Sequential-Lactobacillus group
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential-Lactobacillus group
Study: 16883627
Drug: Chunghyul-dan (CHD)
Normalized name: Dan shen suan b
DrugBank: Salvianolic acid B (DB19313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chunghyul-dan (CHD) 600 mg three times a day for 8 weeks
Study: 14612206
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 2 g/day plus Vitamin E 400 IU/day (Group B)
Study: 14612206
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 2 g/day plus Vitamin E 800 IU/day (Group C)
Study: 2502441
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC)/hMG regimen
Study: 17079573
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of erythropoietin, iron, folate, and vitamin B12
Study: 8742095
Drug: Bicalutamide in
Normalized name: Product containing bicalutamide in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide in combination with LHRH analogs
Study: 27490922
Drug: ω-3 Fatty
Normalized name: ω-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 Fatty Acid Ethyl Esters (4 g/d)
Study: 3805752
Drug: Leukotriene D4
Normalized name: Leukotriene D4
DrugBank: Leukotriene D4 (DB11858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukotriene D4 (LTD4) at doses of 3.1‐200 pmol
Study: 2524387
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of ipratropium bromide (20 mg)
Study: 16434666
Drug: Creatine 8
Normalized name: Creatine 800 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine 8 g/day for 16 weeks
Study: 9625322
Drug: L-ornithine-L-aspartate
Normalized name: ornithine, (L)-isomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-ornithine-L-aspartate
Study: 30565017
Drug: Magnesium and
Normalized name: Calcium, Magnesium and Zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium and Vitamin E co-supplementation (250 mg/day magnesium plus 400 mg/day vitamin E)
Study: 19340731
Drug: Postoperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative administration of omeprazole
Study: 843096
Drug: Corn oil-in-water
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil-in-water emulsion (5, 10, 15, or 30 gm doses containing 250 mg of microsize griseofulvin)
Study: 843096
Drug: Corn oil
Normalized name: Corn Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil (10 gm dose of emulsion)
Study: 28555204
Drug: Fixed-on-2 implants
Normalized name: trenbolone
DrugBank: Trenbolone acetate (DB14660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-on-2 implants
Study: 28555204
Drug: Fixed-on-4 implants
Normalized name: trenbolone
DrugBank: Trenbolone acetate (DB14660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-on-4 implants
Study: 11287371
Drug: COP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: COP treatment
Study: 8770026
Drug: Methylprednisolone (METH)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (METH) intravenous infusion (125 mg/30 min) during weight maintenance diet
Study: 23427865
Drug: Infusion rate
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rate of 0.1 mL/min
Study: 8011000
Drug: Conventional fluorocarbon-containing
Normalized name: fluorocarbon blood substitutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fluorocarbon-containing GTN spray (R)
Study: 31816306
Drug: Outpatient ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Outpatient ibuprofen plus acetaminophen (nonopioid, n=85)
Study: 28824041
Drug: Canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin 100 mg/day + Teneligliptin 20 mg/day
Study: 15057391
Drug: Etching with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etching with 36% phosphoric acid gel - Conditioner 36 (Dentsply) for 20 s, followed by water rinse for 15 s
Study: 29743380
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of cilostazol
Study: 27722854
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg
Study: 7863047
Drug: No Continuous
Normalized name: Lotion, Multi Ingredient Topical application Lotion [AVEENO CONTINUOUS RADIANCE MOISTURIZING LOTION]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Continuous Ambulatory Oxygen Therapy (CAOT) - Group A
Study: 25073921
Drug: Blood solution
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood solution
Study: 11874410
Drug: Physiological hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Physiological hydrocortisone infusion (PHI)
Study: 11715153
Drug: Polysaccharide pneumococcal
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide pneumococcal vaccine
Study: 12619262
Drug: Benzocaine patch
Normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzocaine patch (12 mg)
Study: 22815837
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g type 2 resistant starch
Study: 20974547
Drug: Solution A
Normalized name: I.V. SOLUTION ADDITIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution A (Solo‐care Aqua(®), Ciba‐Vision)
Study: 20974547
Drug: Solution B
Normalized name: DONISLECEL-JUJN RINSE SOLUTION BAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution B (Hidro Health(®), Disop)
Study: 16133961
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg daily
Study: 11809180
Drug: Omeprazole with
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole with placebo antibiotics (placebo group) for 1 week, followed by diclofenac slow release 100 mg daily for 6 months
Study: 11809180
Drug: Omeprazole triple
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole triple therapy (eradication group) for 1 week, followed by diclofenac slow release 100 mg daily for 6 months
Study: 31770287
Drug: Propofol-based total
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-based total intravenous anesthesia (TIVA group, n=25)
Study: 27904000
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil (6 g/d for 8 weeks)
Study: 8474318
Drug: 23 g
Normalized name: PEG-23 GLYCERYL DISTEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23 g parboiled white rice
Study: 16189090
Drug: Ciprofloxacin IR
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin IR 250 mg twice daily for 3 days
Study: 26045549
Drug: Conventional GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional GnRH antagonist protocol (Cetrotide 0.25 mg sc from day 2 to day 8, then Gn therapy added)
Study: 7575051
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg nicotine polacrilex
Study: 23729801
Drug: Ofatumumab 3
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 3 mg
Study: 23729801
Drug: Ofatumumab 30
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab 30 mg
Study: 799560
Drug: Diuretic (Hydrochlorothiazide)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diuretic (Hydrochlorothiazide)
Study: 10949727
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin therapy
Study: 21825093
Drug: Jin Shin
Normalized name: Yu Jin
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jin Shin Jyutsu (JSJ) treatments, 10 weekly sessions
Study: 8027856
Drug: Trace minerals
Normalized name: HERBAL TRACE MINERALS LIQUID,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trace minerals only (15.0 mg zinc/d, 5.0 mg manganese/d, 2.5 mg copper/d)
Study: 11310461
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam (0.4 mg/kg)
Study: 17130429
Drug: Immediate antiepileptic
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antiepileptic drug treatment
Study: 11790928
Drug: Traditional antiarrhythmic
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional antiarrhythmic drug therapy (ADT)
Study: 2184556
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg atenolol and 12.5 mg chlorthalidone (Tenoretic Mite)
Study: 29034644
Drug: Eicosapentaenoic Acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eicosapentaenoic Acid (EPA) 2 g/day for 8 weeks
Study: 31868879
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by radical hysterectomy
Study: 21030369
Drug: Liquid captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liquid captopril formulations
Study: 10165114
Drug: Jet spacer
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Jet spacer device with inhaled beclomethasone dipropionate (0.5 mg twice daily)
Study: 14667957
Drug: Eptifibatide +
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide + Unfractionated Heparin (UFH)
Study: 18290855
Drug: Tadalafil 2.5
Normalized name: tadalafil 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 2.5 mg
Study: 10524634
Drug: UDCA 1200
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 1200 mg/day
Study: 10524634
Drug: UDCA 300
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 300 mg/day
Study: 21310372
Drug: Intracoronary adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary adenosine (1 to 2 mg) administered 2 times during PCI
Study: 22095631
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg every 6 months
Study: 30602032
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg every 3 months
Study: 12645832
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg 1.8-cineol t.i.d.
Study: 2863090
Drug: Terfenadine tablets
Normalized name: terfenadine Oral Tablet
DrugBank: Terfenadine (DB00342)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terfenadine tablets
Study: 27135960
Drug: Intravenous Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Tranexamic Acid (20 mg/kg)
Study: 23218100
Drug: All atypical
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All atypical antipsychotics
Study: 31676585
Drug: Magic therapy
Normalized name: Oxybenzone/Padimate O 3%-7% Topical application Stick [LIPMAGIC THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magic therapy intervention group (n = 34)
Study: 31676585
Drug: Magic therapy
Normalized name: Oxybenzone/Padimate O 3%-7% Topical application Stick [LIPMAGIC THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magic therapy intervention group (n = 47)
Study: 10711866
Drug: Dexamethasone 1.0
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL / DEXAMETHASONE 1.0 mg in 1 mL OPHTHALMIC SUSPENSION/ DROPS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1.0 mg/kg twice a day for 2 days
Study: 7794289
Drug: Autohaler Inhalation
Normalized name: pirbuterol
DrugBank: Pirbuterol (DB01291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Autohaler Inhalation Device (breath-activated MDI)
Study: 3898835
Drug: Sucralfate administered
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate administered every six hours
Study: 9506749
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose triamcinolone acetonide (L TAA, 800 microg/day)
Study: 25432415
Drug: ER niacin
Normalized name: Leader Niacin 500mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER niacin 2 g/day added to atorvastatin 10 mg
Study: 6121605
Drug: nitrazepam 5
Normalized name: nitrazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitrazepam 5 mg
Study: 30429050
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of heart failure medications (after initial 6 months)
Study: 28923098
Drug: Baricitinib monotherapy
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baricitinib monotherapy (4 mg once daily)
Study: 21368386
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 15 mg/d
Study: 19841527
Drug: Routine folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine folic acid supplementation 10 mg/d
Study: 15818702
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg etoricoxib
Study: 24811226
Drug: Nitroglycerin (NG)
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin (NG) dermal patch
Study: 14704645
Drug: Bio-Hep-B vaccine
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-Hep-B vaccine (2.5 microg)
Study: 14704645
Drug: Bio-Hep-B vaccine
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-Hep-B vaccine (5 microg)
Study: 11684212
Drug: Alternate-day rhDNase
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate-day rhDNase (2.5 mg)
Study: 7534320
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone and Conventional medical treatment
Study: 25087308
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (listening to music during surgery)
Study: 17230618
Drug: subcutaneous rhGH
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous rhGH (0.15 IU/kg)
Study: 29405507
Drug: Sham pill
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham pill described as 'a well‐known tablet available without prescription'
Study: 31846499
Drug: rESWT on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: rESWT on antagonist muscles (C)
Study: 25162916
Drug: Infusion prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion prepared from 2, 4, or 8 g of C. citratus leaves once daily for 30 days
Study: 29934395
Drug: Morphine (M)
Normalized name: morphine Extended Release Oral Capsule [M-Eslon]
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (M)
Study: 26160958
Drug: Extended-release nicotinic
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-release nicotinic acid
Study: 17966618
Drug: H2 blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: H2 blocker (famotidine 20 mg)
Study: 27358210
Drug: Brodalumab 140
Normalized name: brodalumab 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodalumab 140 mg
Study: 15679722
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate 100 microg nasal spray
Study: 16260972
Drug: Oral carbohydrate
Normalized name: omega-3 carboxylic acids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbohydrate (CHO) load (carbohydrate‐rich meal) during exercise
Study: 12113564
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg i.v. droperidol over 5 minutes
Study: 27716324
Drug: Sarilumab 200
Normalized name: SARILUMAB 200MG/1.14ML INJ SYR 1.14ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab 200 mg every 2 weeks (q2w)
Study: 26656336
Drug: Artificial infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artificial infusion solutions in the HAS group
Study: 3528612
Drug: Captopril or
Normalized name: captopril Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril or prazosin treatment in Group I patients
Study: 9349064
Drug: Nebulised lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised lignocaine (4 ml 4% lignocaine)
Study: 10547251
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (Amoxicillin/clavulanate and Azithromycin)
Study: 22986318
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) lidocaine 1.5 mg/kg 20 minutes before incision followed by a continuous lidocaine infusion of 1.5 mg/kg/hr until the end of surgery
Study: 25557316
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (1200 IU daily)
Study: 29314350
Drug: Non-cancer treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-cancer treatment group (4-week online program)
Study: 10954953
Drug: Sumatriptan nasal
Normalized name: SUMAtriptan nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan nasal spray (20 mg)
Study: 10954953
Drug: Dihydroergotamine nasal
Normalized name: dihydroergotamine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine nasal spray (1 mg plus optional 1 mg)
Study: 18626271
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (1.6 mg/kg) MDMA
Study: 3614616
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both steroids